Calton & Associates Inc. Trims Stock Holdings in GSK plc (NYSE:GSK)

Calton & Associates Inc. decreased its stake in GSK plc (NYSE:GSK) by 10.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,315 shares of the pharmaceutical company’s stock after selling 715 shares during the quarter. Calton & Associates Inc.’s holdings in GSK were worth $258,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of GSK. Register Financial Advisors LLC purchased a new stake in shares of GSK during the first quarter worth about $31,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of GSK during the second quarter worth about $37,000. PrairieView Partners LLC purchased a new stake in shares of GSK during the second quarter worth about $47,000. Triad Wealth Partners LLC purchased a new stake in shares of GSK during the second quarter worth about $49,000. Finally, Concord Wealth Partners grew its position in shares of GSK by 69.7% during the first quarter. Concord Wealth Partners now owns 1,436 shares of the pharmaceutical company’s stock worth $62,000 after purchasing an additional 590 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Insider Activity

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 10.00% of the company’s stock.

GSK Stock Performance

NYSE GSK opened at $38.00 on Wednesday. The stock has a market capitalization of $78.75 billion, a PE ratio of 13.77, a P/E/G ratio of 1.30 and a beta of 0.65. GSK plc has a 1-year low of $33.67 and a 1-year high of $45.92. The business has a 50 day simple moving average of $41.33 and a two-hundred day simple moving average of $41.21. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. The business had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. On average, research analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were paid a $0.3843 dividend. This represents a $1.54 annualized dividend and a dividend yield of 4.05%. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, August 16th. GSK’s dividend payout ratio (DPR) is presently 55.80%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on GSK shares. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, Jefferies Financial Group raised their price target on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.